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Cells of primary effusion lymphoma (PEL), a B-cell non-Hodgkin’s lymphoma, are latently infected by
Kaposi’s sarcoma-associated herpesvirus (KSHV), with about 80% of PEL also co-infected with
Epstein–Barr virus (EBV). Both viruses can be reactivated into their lytic replication cycle in PEL by
chemical inducers. However, simultaneous activation of both lytic cascades leads to mutual lytic
cycle co-repression. The plasma cell-differentiation factor X-box binding protein 1 (XBP-1)
transactivates the KSHV immediate–early promoter leading to the production of the replication and
transcription activator protein (RTA), and reactivation of KSHV from latency. XBP-1 has been
reported to act similarly on the EBV immediate–early promoter Zp, leading to the production of the
lytic-cycle transactivator protein BZLF1. Here we show that activated B-cell terminal-differentiation
transcription factor X-box binding protein 1 (XBP-1s) does not induce EBV BZLF1 and BRLF1
expressioninPEL andBLcelllines,despiteinducinglytic reactivationofKSHVinPEL.Weshowthat
XBP-1stransactivatestheKSHVRTApromoterbutdoesnottransactivatetheEBVBZLF1promoter
in non-B-cells by using a luciferase assay. Co-expression of activated protein kinase D, which can
phosphorylate and inactivate class II histone deacetylases (HDACs), does not rescue XBP-1 activity
on Zp nor does it induce BZLF1 and BRLF1 expression in PEL. Finally, chemical inducers of KSHV
and EBV lytic replication in PEL, including HDAC inhibitors, do not lead to XBP-1 activation. We
conclude that XBP-1 specifically reactivates the KSHV lytic cycle in dually infected PELs.
INTRODUCTION
The human gammaherpesviruses Epstein–Barr virus (EBV)
and Kaposi’s sarcoma-associated herpesvirus (KSHV) are
associated with B-cell lymphomas and tumours of epithelial
and endothelial origin, respectively. EBV and KSHV co-
infection occurs in approximately 80% of the non-
Hodgkin’s B-cell lymphoma, primary effusion lymphoma
(PEL); the remainder being infected by KSHV alone. KSHV
and EBV dually infected PEL have a subtly different pattern
of B-cell gene expression compared with KSHV singly
infected PEL (Fan et al., 2005). In addition, the presence of
EBV appears to potentiate the tumourigenicity of dually
infected PELs in SCID mice (Trivedi et al., 2004). How
dually infected PEL arise is not understood, however, both
KSHV and EBV latently infect PEL and normal B-cells.
EBV establishes a latent infection in memory B-cells in vivo
(Babcock et al., 1998, 1999; Souza et al., 2005; Thorley-Lawson,
2001). A model for EBV infection suggests that, following
saliva transmission, EBV infects IgD-positive antigen-naı ¨ve
B-cells in the nasopharyngeal lymphoid tissue (Joseph et al.,
2000) and induces B-cell proliferation through the expres-
sion of virus latent growth programme genes (Thorley-
Lawson & Gross, 2004). The EBV-positive lymphoblasts
subsequently express the default/latency II gene-expression
programme (Thorley-Lawson, 2001; Thorley-Lawson &
Gross, 2004), finally entering the memory B-cell repertoire,
where the virus silences its gene expression allowing lifelong
persistence (Gires et al., 1997; Panagopoulos et al., 2004).
The type of B-cell and the mechanism of latent colonization
by KSHV are not known.
Horizontal virus transmission requires either EBV and/or
KSHV to reactivate from latency with infectious EBV and
KSHV being transmitted by saliva. The molecular events
that lead to virus reactivation have been studied extensively.
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viralproteins,BZLF1(ZTA)andBRLF1(RTA)(Amonetal.,
2004; Chang & Liu, 2000; Yuan et al., 2006). BZLF1 is the
key immediate–early protein in EBV (Bryant & Farrell, 2002;
Countryman & Miller, 1985), with B-cell receptor (BCR)
cross-linking able to activate the BZLF1 promoter (Zp) but
not the BRLF1 promoter (Rp). Induction of Zp is therefore
the first event of EBV lytic reactivation (Amon et al., 2004),
and BZLF1 expression alone is sufficient to initiate the entire
EBV lytic cycle (Countryman & Miller, 1985; Rooney et al.,
1989). For KSHV, the virus immediate–early replication and
transcription activator protein (RTA) is both necessary and
sufficient to activate the virus lytic cycle. RTA is able to
transactivate its own promoter and those of many viral
genes, leading to the KSHV lytic gene expression cascade
(Lukac et al., 1998).
The authentic cellular mediators that lead to the induction
of EBV BZLF1 (ZTA) and KSHV RTA (K-RTA) are less
clear. Previously, we and others showed that the activated
B-cell terminal-differentiation transcription factor X-box
binding protein 1 (XBP-1s) is sufficient to initiate the lytic
cycle of KSHV in PEL cell lines (Dalton-Griffin et al., 2009;
Sun & Thorley-Lawson, 2007; Wilson et al., 2007). XBP-1s
binds to and transactivates the promoter of KSHV RTA.
XBP-1s expression is essential for terminal differentiation
of plasma cells (Reimold et al., 2001). XBP-1 retains a 26 nt
intron when expressed (XBP-1u, unspliced) that results in
a frame shift preventing the translation of an active
transcription factor. Under endoplasmic reticulum (ER)
stress or B-cell terminal differentiation, the 26 nt intron of
XBP-1u mRNA is removed to allow the translation of the
active form, XBP-1s (XBP-1 spliced) (Calfon et al., 2002).
EBV lytic replication is induced in plasma cells (Laichalk &
Thorley-Lawson, 2005); however, EBV infection of mul-
tiple myeloma cell lines does not result in lytic EBV
replication even though XBP-1s is abundantly expressed in
these cells (Anastasiadou et al., 2009). Interestingly, other
studies have also suggested that XBP-1s is able to bind to
and transactivate the EBV BZLF1 promoter (Bhende et al.,
2007; Sun & Thorley-Lawson, 2007). Although XBP-1 can
be transiently activated following BCR cross-linking
(McDonald et al., 2010), XBP-1s alone may not be
sufficient to induce expression of EBV ZTA as protein
kinase D (PKD) may also be required (Bhende et al., 2007).
In dually infected PEL a selective lytic switch has been
proposed that leads to the induction of one virus over the
other (Miller et al., 1997). Indeed K-RTA can only induce
the KSHV lytic cycle and BZLF1 can only induce the EBV
lytic cycle in PEL. The selective switch can be maintained
by the induced virus blocking the lytic replication of the
other latent virus (Xu et al., 2007). If both K-RTA and
BZLF1 are expressed at the same time, physical interactions
promote mutual inhibition of the two transcription factors
(Jiang et al., 2008). Here we investigate the mechanism that
underlies the initial induction of K-RTA and BZLF1 in
dually infected PEL (Miller et al., 1997). We show that
XBP-1s alone induces the KSHV lytic cycle but does not
induce either EBV BZLF1 or BRLF1 in PEL cell lines; it also
does not induce either of the EBV immediately–early
proteins in EBV-positive Burkitt’s lymphoma cell lines
(BLs). Additionally, we show that XBP-1s does not activate
the BZLF1 promoter of EBV in HEK 293T and HeLa cells.
Overexpressing XBP-1s in both PEL and BLs does not
increase the level of BZLF1 and BRLF1 mRNA. These
results suggest that XBP-1s activates the KSHV lytic cycle
alone in EBV co-infected PEL cells.
RESULTS
XBP-1s overexpression in PEL cell lines results in
KSHV RTA expression but not EBV BZLF1
expression
In order to examine the ability of XBP-1s to induce the
EBV lytic cycle, we used lentiviral vectors for the transient
delivery of XBP-1s into different PEL cell lines. The effect
of XBP-1s overexpression on both KSHV and EBV were
evaluated by Western blotting against the KSHV imme-
diate–early gene K-RTA and the EBV immediate–early
gene BZLF1 (ZTA), respectively. Overexpressing XBP-1s in
JSC-1 cells, a KSHV and EBV co-infected PEL, induced K-
RTA expression. However, no EBV BZLF1 protein
expression was detected, despite the ability of O-tetradeca-
noyl-phorbol 13-acetate (TPA) to induce the expression of
K-RTA and BZLF1 in JSC-1 simultaneously (Fig. 1a).
It is possible that EBV in PEL cell lines is in some way
defective or non-responsive to XBP-1s. Therefore, we
repeated the experiment with BC3 clone 6 (BC3 cl6) and
CRO6 clone 2 (CRO6 cl2); two cell lines that were
produced by superinfecting KSHV single-positive PEL cell
lines with replication-competent EBV–GFP virus (Xu et al.,
2007). Western blot analysis showed identical results with
the induction of K-RTA but no expression of BZLF1 (Fig.
1b, c) after overexpressing XBP-1s in these cells. TPA
treatment again resulted in induction of K-RTA and
BZLF1. In all cases, 60–80% of PEL cells were transduced
by the XBP-1s-expressing lentivirus (data not shown).
Expression of XBP-1s was confirmed by using Western blot
analysis (Fig. 1a, b). Therefore, XBP-1s induces K-RTA
expression in PELs, but does not induce BZLF1 expression.
Overexpression of XBP-1s in BL cells does not
induce EBV BZLF1 expression
It is possible that the presence of KSHV in PEL affects the
ability of XBP-1s to induce BZLF1 expression. We
therefore expressed XBP-1s in BLs, which are only EBV
positive. Using BCR cross-linking we could induce BZLF1
expression (Fig. 2). However, overexpressing XBP-1s in
two different BL lines, Mutu and Akata, did not induce
BZLF1 expression despite good transduction efficiencies of
10–25%. This suggests that XBP-1s does not transactivate
the BZLF1 promoter in B-cell lymphomas regardless of the
presence of KSHV.
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not induce EBV BRLF1 and BMRF1 expression
BRLF1 is a second EBV immediate–early protein whose
expression is induced by BZLF1 during the EBV lytic cycle.
Together these two proteins induce the rest of EBV lytic
cascade. We examined the expression of BRLF1 after
overexpressing XBP-1s in both BL (Akata) (Fig. 3a) and
PEL (JSC-1) (Fig. 3b) cells. The expression of the EBV
early protein BMRF1, also known as diffused early antigen
(EA-D) (Bayliss & Wolf, 1981), was also examined by
using Western blot analysis. BMRF1 transcription is
activated by BZLF1 (Kenney et al., 1992). However, in
BL or PEL cell lines, overexpression of XBP-1s did not
induce BZLF1, BRLF1 and BMRF1 expression. Inter-
estingly, co-induction of K-RTA, BZLF1 and BRLF1 by
TPA in PEL failed to induce BMRF1 expression, consistent
with mutual co-repression of the full virus lytic cycle
(Jiang et al., 2008).
EBV lytic-cycle promoters do not respond to
XBP-1s
Previously, we showed that XBP-1s can transactivate the K-
RTA promoter (Wilson et al., 2007), thereby inducing the
KSHV lytic cycle. We therefore determined whether the
Fig. 1. XBP-1s does not activate EBV lytic gene expression in PEL
cell lines. (a) JSC-1, a KSHV and EBV double-positive PEL cell
line, expressed K-RTA and BZLF1 after treatment with TPA, but
only K-RTA was expressed following XBP-1s transduction. (b)
BC3 cl6, and (c) CRO6 cl2 are EBV-superinfected KSHV-positive
PEL cell lines and showed a similar pattern with XBP-1s
transduction only resulting in K-RTA expression. TPA was able to
induce both K-RTA and BZLF1. The Daudi cell line treated with
TPA and K-RTA-transfected HEK 293T cells acted as positive
controls for the BZLF1 and K-RTA antibody staining, respectively.
XBP-1s expression was detected using an XBP-1s specific
antibody. VecCon, vector control.
Fig. 2. Burkitt’s lymphoma (BL) cell lines do not express BZLF1
after transduction with XBP-1s. (a) Mutu and (b) Akata, both EBV-
positive BL cell lines, were transduced with XBP-1s and vector
control (VecCon) but BZLF1 expression was not detected. B-cell
surface cross-linking (BCR) with human Ig is used as positive
control to induce BZLF1 expression: (a) Mutu, with Ig-M. (b) Akata,
with Ig-G.
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XBP-1s. A construct containing BZLF1 promoter fused to a
luciferase reporter gene (McDonald et al., 2010) was used
to determine the response to XBP-1s in HEK 293T cells;
however, we were unable to show strong XBP-1s activity on
the BZLF1 promoter (Fig. 4a). The experiments were
repeated using the BRLF1 promoter (Bhende et al., 2007)
in either the methylated or unmethylated form. Both forms
of the BRLF1 promoter were transactivated by BRLF1 and
had a lesser but detectable response to XBP-1s (Fig. 4b).
The activity was therefore independent of the promoter
methylation status. The activity of XBP-1s in this assay
system was confirmed by using a KSHV RTA luciferase
promoter reporter that responded to both KSHV RTA and
XBP-1s (Fig. 4c). The expression of XBP-1s in the
luciferase assay was confirmed by Western blot analysis
(Fig. 4a, b insert).
XBP-1 is unspliced in different B-cell lymphomas
and splicing is not induced by TPA or valporic
acid (VPA)
XBP-1u is expressed in both PEL and BL cell lines. DTT, a
reducing agent able to induce the KSHV lytic cycle in
KSHV-infected HEK 293T cells, can cause the splicing of
inactive XBP-1u mRNA to active XBP-1s mRNA by
promoting the unfolded-protein response (UPR) (Wilson
et al., 2007). As TPA can induce K-RTA and BZLF1
expression, and previous reports show other chemical
agents can induce these viruses (Ye et al., 2007), we
determined whether they do so in part by inducing
XBP-1splicing. DTT, TPA, VPA and sodium butyrate
(NaB) (both histone deacetylase inhibitors) were used and
XBP-1 splicing was assessed in the PEL cell line JSC-1 and
BC3 cl6 cell line. Only DTT caused XBP-1 splicing in PEL
cell lines despite TPA being capable of inducing KSHV K-
RTA and EBV BZLF1 expression (Fig. 5b, c, f). We also
examined the splicing status of XBP-1 in the BL cell lines
Akata and Mutu. Again, XBP-1 is expressed as the
unspliced inactive form and this only undergoes splicing
in the presence of DTT (Fig. 5d, e).
Induction of XBP-1 splicing by the UPR does not
induce the KSHV and EBV lytic cycle
As DTT is capable of inducing XBP-1 splicing and the
KSHV lytic cycle in HEK 293T cells (Wilson et al., 2007),
we examined the ability of DTT to induce the lytic
reactivation of KSHV and EBV by Western blotting for the
expression of K-RTA and BZLF1. Despite being able to
cause XBP-1 splicing, DTT resulted in large amounts of cell
death in PEL (Fig. 5h) After treating the cells with DTT for
10 min, JSC-1 cells lose membrane integrity and stain with
trypan blue; after 48 h of incubation, more than 50% of
JSC-1 cells are dead (Fig. 5h). Therefore, and because of the
toxicity of DTT in PEL cells, it is not possible to access the
effect of XBP-1 splicing (Fig. 5f). The BL cell line Akata was
more resilient to DTT treatment; however, despite the
ability of DTT to induce XBP-1 splicing, BZLF1 was not
expressed (Fig. 5g).
Fig. 3. Expression of XBP-1s does not induce BRLF1 and BRLF1 protein expression in either BL or PEL cell lines. (a) Akata and
(b) JSC-1 cell lines were transduced with XBP-1s and vector control with m.o.i. of 5 and 2, respectively (m.o.i. measured in
JSC-1 cells). Neither BZLF1, BRLF1 nor BMRF1 expression were detected in either cell line. BCR cross-linking was used as a
positive control for Akata to induce EBV lytic gene expression and TPA was used as a positive control for JSC-1 cell lines to
induce KSHV and EBV lytic gene expression. Both positive controls showed strong BZLF1 expression, weaker BRLF1
expression, and, for Akata (a) only, expression of BMRF1 with BCR cross-linking. B95.8 cell line was used as a positive control
for EBV immediate–early and early protein expression.
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agents does not induce expression of BZLF1 and
BRLF1 mRNA in PEL or BL
Although XBP-1s overexpression did not induce detectable
BZLF1 and BRLF1 protein expression in PEL or BL cell
lines, the luciferase assays showed that XBP-1s weakly
transactivated Zp and Rp in HEK 293T cells. We therefore
performed a quantitative real-time PCR (Q-RT-PCR) to
determine the mRNA levels of BZLF1 and BRLF1 in PEL
and BL cell lines in response to XBP-1s and various
chemical inducers of the KSHV and EBV lytic cycles.
In Akata cells, BZLF1 and BRLF1 mRNA expression did not
increase following XBP-1s expression or following TPA,
VPA and DTT treatment (Fig. 6a). BCR cross-linking used
as a positive control induced BZLF1 mRNA expression
significantly (P,0.05, two-tailed t-test). The increase of
BRLF1 mRNA is not statistically significant (P.0.05, two-
tailed t-test) and is consistent with the lack of BRLF-1
protein expression (Fig. 3a). This is also consistent with
previous work by Amon et al. (2004), showing that BCR-
cross-linking transactivates Zp, but not Rp.
EBV BZLF1, EBV BRLF1 and KSHV K-RTA mRNA
expression was determined in JSC-1 cells by using Q-RT-
PCR (Fig. 6b). After XBP-1s transduction or VPA and DTT
treatment, BZLF1 and BRLF1 mRNA expression was not
significantly different from control cells (P.0.05, two-
tailed t-test). However, the K-RTA mRNA level increased
significantly in response to XBP-1s, TPA, VPA and DTT
(P,0.05, two-tailed t-test). TPA induced a significant
increase in the BZLF1 mRNA level, compared with the
negative control (P,0.05, two-tailed t-test). These data
confirm that XBP-1s alone does not transactivate the EBV
Zp or Rp in PEL or BL cell lines.
XBP-1s and protein kinase D together do not
induce BZLF1 expression in PEL cell lines
Previously Bhende et al. (2007) showed that XBP-1s alone
was not sufficient to induce lytic reactivation of EBV and
that PKD was also required. We therefore performed
luciferase assays to investigate the effect of the combined
expression of XBP-1s and a constitutively active PKD
(pPKDm-IG). In HEK 293T cells, PKD alone weakly
transactivated the BZLF1 promoter but not the BRLF1
promoter (Fig. 7a). Conversely, XBP-1s in combination
with PKD weakly transactivated the BRLF1 promoter (Fig.
7a). In order to ensure that the lack of a robust effect from
PKD is not cell type specific, we performed the luciferase
assay in HeLa cells for the Zp. Here, XBP-1s and active
PKD alone do not transactivate Zp, but together weakly
transactivate Zp (Fig. 7b). However, these effects are not
statistically significant (P.0.05, two-tailed t-test). At all
times BZLF1 and BRLF1 were able to transactivate their
respective promoters.
Importantly, overexpressing either PKD or XBP-1s alone or
together in JSC-1 cells did not induce BZLF1 or BRLF1
protein expression (Fig. 7c), whereas K-RTA expression was
induced whenever XBP-1s was overexpressed. Q-RT-PCR
confirmed that the mRNA expression of BZLF1 and BRLF1
did not increase when PKD was expressed with and without
XBP-1s (Fig. 7d). K-RTA mRNA expression increased
significantly (P,0.05, two-tailed t-test) whenever XBP-1s
Fig. 4. BZLF1 and BRLF1 promoter responses to XBP-1s. (a)
XBP-1s weakly transactivates the Zp in a luciferase-reporter assay
in HEK 293T cells. BZLF1 overexpression transactivates the Zp as
a positive control. (b) BRLF1 and XBP-1s expression transactivate
the Rp. The XBP-1s expression level in Zp- (d, insert) and Rp- (e,
insert) transfected cells co-transfected with BZLF1, BRLF1 or
XBP-1s was determined by Western blotting. (c) The K-RTA
promoter was used as a positive control for XBP-1s expression
and activity. The promoter is transactivated by both K-RTA and
XBP-1s. RLU, Relative light units.
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does not lead to EBV BZLF1 and EBV BRLF1, or KSHV
K-RTA expression. Also, active PKD together with XBP-1s
does not induce EBV BZLF1 and BRLF1 expression.
DISCUSSION
Plasma cell terminal differentiation and the associated
expression of XBP-1s are linked to EBV and KSHV lytic
cycle induction (Bhende et al., 2007; Laichalk & Thorley-
Lawson, 2005; Sun & Thorley-Lawson, 2007; Wilson et al.,
2007; Yu et al., 2007). Recently this has been extended
beyond human gammaherpesviruses with the demonstra-
tion that plasma cells account for most of the lytic
reactivation of murine herpesvirus 68 in mice (Liang et al.,
2009). In EBV and KSHV co-infected PEL however,
selective induction of one viral lytic cycle cross-represses
the other viral lytic cycle and co-expression of both KSHV
Fig. 5. NaB, TPA and VPA do not induce XBP-1 splicing in PEL and BL cell lines. (a) XBP-1 is expressed as an unspliced
(XBP-1u) form, but the spliced, active form (XBP-1s) can be detected following ER stress induction by the resistance to PstI
digestion of the XBP-1s PCR product. Treating the cells with DTT induces ER stress and XBP-1u splicing in all lymphoma cell
lines (b–e). However, NaB, TPA and VPA treatment do not induce XBP-1 splicing in the lymphoma cell lines (b–e) even though
VPA induces K-RTA expression in the PEL JSC-1 and TPA induces both K-RTA and BZLF1 in JSC-1 cells (f). VPA and DTT do
not induce BZLF1 expression in the BL line Akata (g). DTT toxicity (h) results in PEL cell death and the absence of detectable
proteins (f).
I. Y.-C. Lai, P. J. Farrell and P. Kellam
426 Journal of General Virology 92and EBV immediate–early proteins results in mutual
inhibition (Jiang et al., 2008; Miller et al., 1997; Xu et al.,
2007). This suggests that a selective lytic switch that
induces one or other virus is required for successful EBV or
KSHV lytic replication in PEL. Here we show that XBP-1s
is able to induce KSHV lytic replication alone in dually
infected PEL. XBP-1s does not induce the expression of
EBV BZLF1 and BRFL1 immediate–early–proteins or
transcripts in PEL or BL. XBP-1s with PKD also does not
induce the expression of BZLF1 and BRFL1 immediate–
early proteins or transcripts in PEL.
Previous studies have suggested XBP1s, either alone or in
combination with PKD, can activate the EBV lytic cycle
(Bhende et al., 2007; Sun & Thorley-Lawson, 2007);
however, the mechanistic detail is unclear. Sun &
Thorley-Lawson (2007) showed that, in HeLa cells, XBP-
1s cannot transactivate Zp. Whereas, Bhende et al. (2007)
showed, also in HeLa cells, that XBP-1s weakly transacti-
vates Zp and Rp, and the effect on Zp could be enhanced
by co-expression of constitutively active PKD (Bhende
et al., 2007; Sun & Thorley-Lawson, 2007). Our data in
HEK 293T cells supports the observations that XBP-1s
alone can weakly transactivate Zp and Rp. Similarly, we
show co-expression of XBP-1s and PKD weakly transacti-
vates Zp in HEK 293T and HeLa cells, although not to the
magnitude described previously. This may reflect differ-
ences in assay sensitivity or may reflect the fact that we
have used human XBP-1s in our studies rather than the
murine XBP-1s used by Bhende et al. (2007). Nevertheless,
the relevance of these observations in HEK 293T and HeLa
cells, and the response of EBV to XBP-1s and PKD in B-cell
tumour lines, is questionable.
The ability of XBP-1s to transactivate either Zp or Rp
probably depends on both the cell type and on the nature
of the individual cell lines. This is supported by observa-
tions that distinct chemical inducing agents have different
effects on the induction of EBV and KSHV lytic cycles in
various lymphoma lines (Countryman et al., 2008; Miller
et al., 1997). In a lymphoblastoid and a nasopharyngeal
carcinoma cell line XBP-1s and PKD clearly activated EBV
BZLF1 protein expression, but BL or PEL cell lines were
not tested (Bhende et al., 2007). In an unusual multiple-
myeloma cell line latently infected with EBV, only low
levels of BZLF1 transcript could be induced by XBP-1s.
This observation contrasts with recent data indicating that
EBV can latently infect multiple myeloma cell lines in vitro.
In these circumstances the endogenous, active XBP-1s does
not drive the EBV lytic cycle (Anastasiadou et al., 2009).
Here we show that despite transactivation of Zp and Rp by
XBP-1s in HEK 293T cells, there are no detectable levels of
BZLF1 and BRLF1 mRNA or proteins after XBP-1s
overexpression in B-cell tumour lines.
Why EBV Zp is refractory to XBP-1s in PEL and BL, even
when PKD is co-expressed, is not clear, although the role of
the chromatin structure at Zp is likely to be important.
Indeed, the binding of myocyte enhancer factor 2D to Zp
recruits class II histone deacetylases (HDACs), which
presumably promote a repressed chromatin structure on
Zp in lymphoma cell lines (Gruffat et al., 2002; McDonald
Fig. 6. Overexpression of XBP-1s in PEL and BL cell lines does not increase the mRNA expression levels of BZLF1 and BRLF1.
Q-RT-PCR was used to determine the expression of BZLF1 mRNA (open bars), BRLF1 mRNA (grey bars) and K-RTA mRNA
(black bars) after transduction with XBP-1s lentivirus or treatment with chemical inducers for (a) Akata and (b) JSC-1 cell lines.
(a) Neither XBP-1s overexpression nor TPA, VPA or DTT treatments were able to increase BZLF1 or BRLF1 mRNA expression.
BCR cross-linking induced BZLF mRNA expression (P,0.05, two-tailed t-test). (b) In JSC-1 cells, expression of XBP-1s only
increased K-RTA mRNA expression. TPA, VPA and DTT treatment also increased K-RTA mRNA expression significantly
(P,0.05, two tailed t-test). TPA-treated JSC-1 cells expressed BZLF1 mRNA compared with negative control (P,0.05, two
tailed t-test).
XBP-1 only induces the KSHV lytic cycle in dually infected PEL
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PKD was suggested as the mechanism that allows XBP-1s
to activate Zp (Bhende et al., 2007). PKD is a member of
the serine/threonine protein kinase family (Rey et al., 2006)
which can be activated by protein kinase C (PKC) (Zugaza
et al., 1996), a cellular target of phorbol esters such as
TPA (Wang, 2006). PKD can also be activated by BCR
cross-linking via the PKC pathway (Matthews et al., 2000).
In our hands, TPA induces both K-RTA and BZLF1 in PEL
and BCR cross-linking induces BZLF1 in BL. Activated
PKD can phosphorylate and therefore inactivate class IIa
HDACs; this is similar to the effect of HDAC inhibitors
(HDACi), such as trichostatin A (Chang & Liu, 2000), VPA
(Feng & Kenney, 2006) and sodium butyrate (NaB). As
Fig. 7. Co-expression of XBP-1s and active PKD does not transactivate Zp or induce BZLF1 expression. (a) HEK 293-T-cells
were transduced with Zp (black bars) or Rp (open bars) luciferase-reporter vectors with either active PKD or XBP-1s together
with active PKD. Active PKD alone shows weak Zp activity and together with XBP-1s weak Rp activity compared to control
empty vector (VecCon) and BZLF1 or BRLF1 expression vectors. However, the increase of luciferase activity was not
statistically significant compared to vector control (P.0.05, two-tailed t-test). (b) The Zp promoter assays were repeated in
HeLa cells where only XBP-1s and PKD together showed weak promoter activity compared with BZLF1 overexpression.
However, this was not statistically significant compared to vector control (P.0.05, two tailed t-test). RLU, Relative light units.
(c) Transduction of JSC-1 cells with XBP-1s and active PKD either alone, in combination or sequentially (denoted by arrows)
does not induce BZLF1, BRLF1 or BMRF1 expression in PEL, but all combinations that include XBP-1s induce K-RTA
expression. (d) mRNA expression in JSC-1, measured by Q-RT-PCR after XBP-1s and/or active PKD transduction for BZLF1
mRNA (open bars), BRLF1 mRNA (grey bars) and K-RTA (black bars). Only K-RTA mRNA expression increased significantly
(P,0.05, two tailed t-test) after XBP-1s transduction with or without PKD expression.
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in various cell lines (Gradoville et al., 2002), we
investigated whether XBP-1s is also induced by any of
these chemical inducers. Here we show that neither NaB,
VPA nor TPA induce activated XBP-1s in PEL, and
therefore the effects of HDACi and TPA on the Zp is
independent of XBP-1s.
BCR cross-linking induces the EBV lytic cycle and can also
transiently induce XBP-1s production. However, this
transient XBP-1s cannot be unambiguously linked to
BZLF1 expression (McDonald et al., 2010). In this study
we used DTT to chemically induce XBP-1s in PEL and BL
cell lines. Although DTT is able to induce XBP-1 splicing
and K-RTA in an XBP-1s dependent manner in HEK 293T
cells (Wilson et al., 2007), it causes a large amount of cell
death in PEL cells, making it impossible to determine K-
RTA, BZLF1 or BRFL1 protein expression. Nevertheless, K-
RTA mRNA expression was detected following DTT
treatment of PEL (Fig. 6b). Also DTT does not cause cell
death in BL cells; it induces XBP-1s production but does
not induce BZLF1 expression. Taken together these data
suggest that induction of the EBV lytic cycle in lymphoma
cell lines of PEL and BL is not linked to XBP-1s activity,
although the effects in B-cells in vivo may be different.
METHODS
Cell culture. The PEL cell line JSC-1 and the BL cell lines Mutu,
Daudi and Akata were grown in RPMI 1640 medium (Invitrogen)
with 10% FCS (BioSera), 100 units penicillin ml
21 and 100 units
streptomycin ml
21 (Invitrogen) at 37 uCi n5 %C O 2. All super-
infected PEL cell lines, CRO6 clone 2, BC3 clone 6 and BC3 clone 10
(a kind gift from Pankaj Treviti), were grown with G418 selection as
described previously (Xu et al., 2007). HEK 293T cells and HeLa cells
were grown in Dulbecco’s modified Eagle’s medium (Invitrogen)
with 15 and 10% FCS, respectively, 100 units penicillin ml
21
and 100 units streptomycin ml
21 (Invitrogen) at 37 uCi n1 0 %
CO2. To induce BZLF1 and K-RTA expression, cells were cultured
with the following concentrations of inducing agents: DTT, 2 mM;
goat anti-human IgG antibody (Sigma), 5 mgm l
21; 12-O-tetradeca-
noyl-phorbol 13-acetate (TPA; Sigma), 20 ng ml
21; VPA (Merck),
1.5 mM.
Lentiviral vector construction and transduction. The lentiviral
vector construction of pXBP1sIG and pIG has been described
previously (Wilson et al., 2007). The lentiviral vector for activated
PKD, pPKDm-IG, was produced from the pHA.PKD.S738A/S742A
plasmid kindly supplied by Alex Toker (Storz & Toker, 2003)
(Addgene). Briefly, BamHI and XhoI were used to clone the
HA.PKD.S738A/S742A insert into the lentiviral vector pIG to produce
the pPKDm–IG construct. To produce lentiviral viruses, HEK 293T
cells were transfected with 1 mg pMDG, 1 mg p8.91 and 1.5 mgo f
lentiviral vector, by using FuGENE-6 (Roche). The supernatants were
collected 48 and 72 h post-transfection and filtered. Both PEL and BL
cell lines (5610
4 cells per well in a 24-well plate) were transduced
with lentivirus vector at an input equivalent to an m.o.i. of 2 or 5 as
measured in JSC-1 cells. This resulted in an actual level of infection of
60–80% in PEL and 10–25% in BL cell lines. Lentiviruses were added
to the cells, spinoculated for 1 h, at 500 g and room temperature. No
selection for infected cells was used after the transduction. Forty-eight
hours after transduction the cells were analysed using flow cytometry.
RNA extraction and reverse-transcriptase PCR (RT-PCR). Total
RNA was purified from 8–10610
5 cells resuspended in TRIzol
(Invitrogen). The TRIzol mixture was first treated with chloroform
and RNA was isolated using an RNA extraction kit (Qiagen),
including an on-column DNase (Promega) digestion. Reverse
transcription was carried out using Ominiscript Reverse
Transcriptase (Qiagen) according to the manufacturer’s instructions
with 1–2 mg total RNA.
PCR and restriction digestion. Oligo-dT (Promega)-primed cDNA
was used for PCR amplification across the XBP-1 intron as described
previously by Wilson et al. (2007). The PCR product was then
digested with PstI for 1 h at 37 uC.
Q-RT-PCR for mRNA. Q-RT-PCR was performed with a QuantiTect
SYBR Green PCR kit (Qiagen) using the following primers: BZLF1
(59-CTATCAGGACCTGGGAGGGC-39 and 59-CACAGCACACAA-
GGCAAAGG-39) (Schelcher et al., 2005), BRLF1 (59-AATTTAC-
AGCCGGGAGTGTG-39 and 59-AGCCCGTCTTCTTACCCTGT-39)
(Chia et al., 2008), K-RTA (59-TTGGTGCGCTATGTGGTCTG-39
and 59-GGAAGGTAGACCGGTTGGAA-39) (Caselli et al., 2005) and
L32 (59-CAACATTGGTTATGCAAGCAACA-39 and 59-TGACGTTG-
TGGACCAGGAACT-39) (Schelcher et al., 2005). L32 is a cellular
ribosomal gene used to assess the preparation of cDNA and all the
mRNA levels were normalized with L32. The PCR was prepared
according to the manufacturer’s instructions and was performed by
using an ABI Prism 7000 (Applied Biosystems) with the following
programme: 50 uC for 2 min, 95 uC for 15 min, 95 uC for 15 s and
60 uC for 1 min; the third and fourth steps are then repeated for
40 cycles.
Luciferase promoter assays. HEK 293T cells or HeLa cells were
plated at a density of 2610
4 cells per well in 96-well plates. Cells were
transfected the next day with 20 ng of the appropriate reporter and
expression constructs by using fuGENE-6 (Roche). The ORF50
reporter plasmids were a kind gift from Erle Robertson (Robertson &
Ambinder, 1997). The BZLF1 promoter and expression vectors have
been described previously (Bryant & Farrell, 2002) and the BRLF1
promoter and expression constructs were a kind gift from Shannon
Kenney (Bhende et al., 2007). The pXBP1sIG and pIG plasmids were
described previously (Wilson et al., 2007). Co-transfection of 2 ng of
Renilla expression vector (a kind gift from Professor Gary Stein,
University of Massachusetts, MA, USA) was also used for monitoring
transfection efficiency. After 48 h, the relative light units (RLU) and
the expression of the Renilla construct were determined using
luciferase Stop & Glo reagents (dual-luciferase assay kit; Promega)
according to the manufacturer’s instructions. Data were read using a
GloMaz96 microplate luminometer (Promega) with a single injector.
All assays were performed in triplicate.
Methylation of promoter luciferase constructs. BRLF1 promoter
was methylated using CpG methyltransferase (New England Biolabs)
according to the manufacturer’s instructions. Methylation of the
plasmids was confirmed by performing restriction enzyme digestion
with methylation-sensitive enzymes. Rp was digested with BgII and
MlnI.
Immunoblotting. Forty-eight hours after transduction (with no
selection), the samples were lysed with a mixture of 1 M DTT and
sample buffer (1:3 ratio) (0.2 M Tris-HCL pH 6.8, 5.2% SDS, 20%
Glycerol and bromophenol blue) then sonicated and heated to 95 uC
for 5 min. Proteins were resolved on 10% polyacrylamide gels by
SDS-PAGE and transferred to a PVDF membrane. The membrane
was blocked with 5% non-fat dried milk powder (NFDM) in TBS
solution containing 0.1% Tween 20 (Sigma) (TBS-T) for 1 h. The
membrane was then probed with primary antibody as follows: BZLF1,
BZ-1 diluted 1:2000 (Bryant & Farrell, 2002); tubulin, anti-a-tubulin
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of Don Ganem (Lukac et al., 1998), diluted 1:40000; PKD, PKC m(D-
20), sc-935 (Santa Cruz) diluted 1:2000; BRLF1, anti-EBV transcrip-
tion factor R (Argene) diluted 1:2000; BMRF1, EBV early antigen
diffuse (Vector Laboratories) diluted 1:2000; XBP-1s, a kind gift
from Giovanna Roncador, diluted 1:50 (Maestre et al., 2009), all in
1% NFDM in TBS-T solution at 4 uC overnight. The membrane was
then incubated with appropriate HRP-conjugated secondary anti-
bodies (GE Healthcare) in 1% NFDM TBS-T solution for 1 h at
room temperature. The blots were washed five times for 5 min
periods in TBS-T before developing, and were visualized using ECL
Western blotting detection reagents or ECL Advanced Western
blotting detection reagents (GE Healthcare).
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